Rhizoma coptidis can inhibit the excessive proliferation, inflammation, and transformation of lung fibroblasts into myofibroblasts

Main Article Content

Jie Yang
Yuting Huang
Zhimin Cui
Chang Liu
Guofang Xie

Keywords

Rhizoma coptidis (COP), FMT, inflammation, Nrf2/HO-1 pathway, pulmonary fibrosis (PF)

Abstract

Background: Pulmonary fibrosis (PF) is a chronic, progressive, and irreversible heterogeneous disease of lung interstitial tissue. To combat progression of PF, new drugs are required to be developed. Rhizoma coptidis (COP), one of the main alkaloids of Coptis chinensis, is a traditional herbal medicine used to treat various inflammatory diseases.


Objective: To investigate the possible effects of Coptisine (Cop) on the growth, inflammation, as well as FMT of TNF-β1-induced HFL1 cells and uncover the mechanism.


Material and Methods: Human fetal lung fibroblast 1 (HFL1) was induced using 6ng/mL TGF-β1 as a model of pulmonary fibrosis. CCK-8, Brdu, and transwell assays indicated the effects on cell growth as well as motility. qPCR and the corresponding kits indicted the effects on cell inflammation. Immunoblot showed the effects on FMT and further confirmed the mechanism.


Results: Coptisine inhibits excessive growth as well as motility of TNF-β1-induced HFL1 cells. It further inhibits inflammation and ROS levels in TNF-β1-induced HFL1 cells. Coptisine inhibits the FMT process of TNF-β1-induced HFL1 cells. Mechanically, coptisine promotes the Nrf2/HO-1 pathway.


Conclusion: Coptisine can inhibit the excessive growth, inflammation as well as FMT of lung fibroblasts into myofibroblasts. It could serve as a promising drug of PF.

Abstract 108 | PDF Downloads 172 HTML Downloads 0 XML Downloads 6

References

1. Thannickal VJ, Toews GB, White ES, Lynch JP, 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395–417. 10.1146/annurev.med.55.091902.103810

2. Koudstaal T, Funke-Chambour M, Kreuter M, Molyneaux PL, Wijsenbeek MS. Pulmonary fibrosis: From pathogenesis to clinical decision-making. Trends Mol Med. 2023;29(12):1076–87. 10.1016/j.molmed.2023.08.010

3. Yi XM, Li M, Chen YD, Shu HB, Li S. Reciprocal regulation of IL-33 receptor-mediated inflammatory response and pulmonary fibrosis by TRAF6 and USP38. Proc Natl Acad Sci USA. 2022;119(10):e2116279119. 10.1073/pnas.2116279119

4. Wu J, Luo Y, Jiang Q, Li S, Huang W, Xiang L, et al. Rhizoma coptidis from Coptis chinensis blocks NLRP3 inflammasome activation by inhibiting caspase-1. Pharmacol Res. 2019;147:104348. 10.1016/j.phrs.2019.104348

5. Wu J, Luo Y, Deng D, Su S, Li S, Xiang L, et al. Rhizoma coptidis from Coptis chinensis exerts diverse beneficial properties: A concise review. J Cell Mol Med. 2019;23(12):7946–60. 10.1111/jcmm.14725

6. Huang J, Ren K, Huang L. Rhizoma coptidis attenuates sepsis lung injury by suppressing LPS-induced lung epithelial cell inflammation and apoptosis. Allergol Immunopathol (Madr). 2023;51(6):30–6. 10.15586/v51i6.972

7. Jo HG, Park C, Lee H, Kim GY, Keum YS, Hyun JW, et al. Inhibition of oxidative stress induced-cytotoxicity by Rhizoma coptidis in V79-4 Chinese hamster lung fibroblasts through the induction of Nrf-2-mediated HO-1 expression. Genes Genomics. 2021;43(1):17–31. 10.1007/s13258-020-01018-3

8. Rao PC, Begum S, Sahai M, Sriram DS. Rhizoma coptidis--induced cell cycle arrest at G2/M phase and reactive oxygen species-dependent mitochondria-mediated apoptosis in non-small-cell lung cancer A549 cells. Tumour Biol. 2017;39(3):1010428317694565. 10.1177/1010428317694565

9. Savin IA, Zenkova MA, Sen’kova AV. Pulmonary fibrosis as a result of acute lung inflammation: Molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches. Int J Mol Sci. 2022;23(23):14959. 10.3390/ijms232314959

10. Kinoshita T, Goto T. Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: A review. Int J Mol Sci. 2019;20(6):1461. 10.3390/ijms20061461

11. Xiaoshen Zhang LC. MiR-216b modulates cisplatin resistance and stem cell-like features in breast cancer cells by targeting E2F4. Trop J Pharm Res. 2023;22(1). 10.4314/tjpr.v22i1.1

12. Saha P, Talwar P. Idiopathic pulmonary fibrosis (IPF): Disease pathophysiology, targets, and potential therapeutic interventions. Mol Cell Biochem. 2023. 10.1007/s11010-23-04845-6

13. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339–50. 10.1084/jem.20110551

14. Zhang R, Tian S, Zhang T, Zhang W, Lu Q, Hu Q, et al. Antibacterial activity mechanism of Rhizoma coptidis against Pasteurella multocida. Front Cell Infect Microbiol. 2023;13:1207855. 10.3389/fcimb.2023.1207855

15. Zhou L, Yang F, Li G, Huang J, Liu Y, Zhang Q, et al. Rhizoma coptidis induces apoptosis in human hepatoma cells through activating 67-kDa laminin receptor/cGMP signaling. Front Pharmacol. 2018;9:517. 10.3389/fphar.2018.00517

16. Zhang Q, Liu J, Duan H, Li R, Peng W, Wu C. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J Adv Res. 2021;34:43–63. 10.1016/j.jare.2021.06.023

17. Ren K, Pei J, Guo Y, Jiao Y, Xing H, Xie Y, et al. Regulated necrosis pathways: A potential target for ischemic stroke. Burns Trauma. 2023;11:tkad016. 10.1093/burnst/tkad016

18. Wang Y, Wei J, Deng H, Zheng L, Yang H, Lv X. The role of Nrf2 in pulmonary fibrosis: Molecular mechanisms and treatment approaches. Antioxidants (Basel). 2022;11(9):1685. 10.3390/antiox11091685